| Business Summary | | Hybridon,
Inc.
utilizes
chemically
modified
synthetic
DNA
for
medical
applications,
including
the
discovery
and
development
of
genetically
based
drugs,
which
treat
diseases
by
acting
on
a
particular
gene.
The
genetic
drugs
being
developed
by
Hybridon
are
based
on
"antisense"
technology,
in
that
they
use
synthetic
DNA
material,
also
called
oligonucleotides,
with
the
aim
of
inhibiting
or
reducing
the
body's
production
of
proteins
that
directly
or
indirectly
cause
or
support
a
given
disease.
Hybridon
has
also
developed
a
portfolio
of
chemically
modified
DNA
compounds
designed
to
stimulate
responses
of
the
immune
system.
Hybridon
has
developed
and
owns
certain
medicinal
chemistry
innovations
useful
in
the
design
of
new
synthetic
DNA
compounds.
Hybridon
also
has
rights
to
technology
allowing
the
chemical
modification
of
synthetic
DNA. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Hybridon
is
engaged
in
the
discovery
and
development
of
novel
genetic
medicines
based
primarily
on
antisense
technology.
For
the
six
months
ended
6/30/01,
revenues
totalled
$552
thousand,
up
from
$153
thousand.
Net
loss
from
continuing
operations
applicable
to
Common
before
extraordinary
item
fell
76%
to
$1.6
million.
Revenues
reflect
collaboration
and
license
agreements
Isis
and
EpiGenesis.
Lower
loss
reflects
a
$6.9
million
gain
on
the
sale
of
Methylgene,
Inc.
shares. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY2000 Pay | |
| James Wyngaarden, M.D., 76 Chairman | -- | Stephen Seiler, 45 CEO,
Director | -- | Sudhir Agrawal, 47 Pres,
CSO | $381K | Youssef El-Zein, 52 Vice
Chairman | -- | Robert Andersen, 50 CFO,
VP-Operations and Planning,Treasurer, Assistant Sec. | 245K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|